BENDAMUSTINE IN ASSOCIATION WITH RITUXIMAB AS SALVAGE THERAPY FOR SPLENIC MARGINAL ZONE LYMPHOMA

At present, a prospectively validated treatment for SMZL is lacking. Despite this fact, splenectomy is still deemed to be the best choice for patients requiring treatment. Nevertheless, the high fraction of patients achieving a clinical response following splenectomy eventually relapses or progresses